Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients-Reference-Cited by-同舟云学术

Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients

Published:2024-03-11 Issue:3 Volume:19 Page:411-421
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Onoi Keisuke,Yamada Tadaaki^ORCID,Morimoto Kenji,Kawachi Hayato,Tsutsumi Rei,Takeda Takayuki,Okada Asuka,Tamiya Nobuyo,Chihara Yusuke,Shiotsu Shinsuke,Takemura Yoshizumi,Yamada Takahiro,Hasegawa Isao,Katayama Yuki,Iwasaku Masahiro,Tokuda Shinsaku,Takayama Koichi

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11523-024-01045-0.pdf

Reference28 articles.

1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48. https://doi.org/10.3322/caac.21763.

2. Marosi C, Köller M. Challenge of cancer in the elderly. ESMO Open. 2016;1:e000020. https://doi.org/10.1136/esmoopen-2015-000020.

3. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078–92. https://doi.org/10.1056/NEJMoa1801005.

4. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288–301. https://doi.org/10.1056/NEJMoa1716948.

5. West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:924–37. https://doi.org/10.1016/S1470-2045(19)30167-6.